Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

First-Ever Transmitted Cases of Alzheimer’s Linked to Growth Hormone Treatment

Scientists have made a groundbreaking discovery in the field of Alzheimer’s disease, documenting the first-ever transmitted cases of the condition. The cases are linked to a now-discontinued medical procedure involving the use of growth hormone derived from human cadavers. The findings, published in the journal Nature Medicine, have shed new light on the potential causes of Alzheimer’s.

What makes these cases particularly unusual is the age of the patients affected. Unlike typical Alzheimer’s patients, these individuals were in their 30s, 40s, and 50s and did not possess the known genetic mutations associated with early-onset Alzheimer’s. Their common history traced back to childhood, where they had received growth hormone treatments derived from human cadavers to address conditions causing short stature.

Decades later, these individuals began exhibiting signs of Alzheimer’s, leading researchers to investigate the potential link between the hormone treatment and the development of the disease. The study revealed that the hormone transplant had inadvertently transferred beta-amyloid protein, a key hallmark of Alzheimer’s, into the recipients’ brains. Over time, this protein propagated into disease-causing plaques, marking the first documented cases of transmitted Alzheimer’s.

Ben Wolozin, an expert on neurodegenerative diseases at Boston University’s medical school, commented on the significance of the findings, stating, “It looks real that some of these people developed early-onset Alzheimer’s because of that [hormone treatment].”

External experts have also validated the legitimacy of the findings, emphasizing that only individuals who received cadaveric growth hormone prepared in a specific manner went on to develop dementia. These incidents of illness resulting from medical procedures are termed ‘iatrogenic,’ with the transmissible agents known as prions, which are misfolded pieces of protein that lead to disease.

The discovery of transmitted Alzheimer’s disease has introduced a new dimension to the ongoing debate surrounding the causes of the condition. The study’s findings have sparked further discussions within the scientific community, offering valuable insights into the potential mechanisms underlying Alzheimer’s and its development.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *